This drug seems to improve electrical markers by four times more than the current standard of care drug, which is a medication called donepezil (Aricept),” Prof Macfarlane said.
The result, which came after 36 days of therapy, is already higher than what donepezil reaches after six months of taking it continuously.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Prof Macfarlane said.
Patients and carers were so impressed with the changes that they are now trying to double the period of time they can access the drug.
BTW, he is going to Barcelona to present complete 2A results.
why would he fly doctor from Austrialia to Barcelona to present the results ? All this means results for 2A part A and B will be really good. Read between the leaves.
today some folks wanted to sell, so they sold. Doesn't change anything about the science, the market it serves, the fact there is nothing today, AXON selling at 1.6 billion market cap with #$%$ drug. AVXL still dirt cheap at 400M. I see at least 800M market cap on Monday.
when they disclose results on Nov 7.
If he knows results are not going to be good, he would not be flying so many people to Barcelona, or do the R/S.
He know with great results, stock will do much better on NAS and over $5 where funds will buy.
bashers are working overtime here, so there might be a small dip in the morning...stock goes to mid 7s, but from that point on its UPTIME...it will bounce back strong and end day mid 9s. This will show instutional buying. Shorts will be covering 1st thing in the AM.
NOTHING in the preso has shown anything negative...fantastic stats vs. SOC (DPZ) at week 5. AXON even cannot beat these results at JUST week 5.
CEO will also come up with PR which will be very positive, as it will be in biz language, not scientific like the 15 min preso. May talk forward looking statemnts - when will phse 2/3 start, partnerships etc.
that is already proven. But if you look at their preso, after 6 months, the standard is getting close to 2-73 was at 36 days. So the big question is...what is the % effectiveness of 2-73 after 6 months, vs 6 months of standard ? I am glad they are going to give 6 months, and 52 weeks partial results too. That will show longer term how effective 2-73 is going to be with daily dosing.
They showed fantastic results, consistent with July results. Company going into ph 2/3, same as AXON going into ph 3...but results so far are far superior than AXON at 1/5 market cap.
we should be AT LEAST $500- $800 MILLION market cap. FDA obviously does not think this is a fraud.
 They will not start phase 2/3 till they get more 12 month data from 2a. They made that clear. So don't expect any news of enrollment for 2/3 till mid 2016 MINIMUM.
 There is going to be NO partnership, despite the hype of the pumpers. No partner is going to put money in a company with only phase 2a.
 Dilution is coming that is for sure. Either thru stock dilution or selling to Lincoln.
 Unfortunately AF is right.....Japanese company already did sigma -1 AZ, and it failed. Pumpers are saying chemical composition is different, but this puts AVXL at VERY HIGH RISK.
 The company is putting positive spin on interim results...but it is such small N, off and on, this is really bad. Something is not right. If PRAN can do placebo in 2A, why didn't AVXL.
 Management is definitely pumping...too similar to pump for PRAN, and the Japanese drug. Same doctor said the SAME pump for PRAN.
Guys this is NO miracle drug...sorry to burst your bubble.
all indications are up, better than SOC, going into ph 2/3, priced 1/5 that of AXON with way better numbers at week 5.
Did they expect the company to announce cure of ALZ in Ph 2A, and get FDA approval on Monday ?? They showed safety and tolerance, they showed effenciency and great cognition readout. AXON and DPZ nowhere near this...P300 had 80% improvement over 'baseline' (meaning SOC DPZ).
It already corrected 40% last 2 days, stock at 250M market cap....AXON at 1.6 billion..what is not to like ?
we don't know what was actually said by the 4 people that presented it. Tomorrow in the PR there will be much more information - business updates, next timelines for 2/3, more details on the 2a and ongoing part 2.
Too many people here guessing...Dr. M will clear things up. He did not do a R/S for no reason..he knows the science is the best there is today.
Shorts are cherry picking that it is not perfect results...yes it is not perfect. But what we have today is WAY from perfect, and what are in trials - AXON - does not come close to AVXL scores...that are compared to baseline (WHICH IS SOC - DPZ)..much better comparison than placebo.
AXVL is top of the game in the field of ALZ treatment and REVERSAL...nothing in the market or trials have this result. So what valuation should we give AVXL ? The market is $20 billion.
Here is your answer after he announced early enrollment completed -
Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We look forward to the full ANAVEX 2-73 Phase 2a trial results and our team is excited to continue moving this clinical program forward.”
Why would he say 'excited about continuing...' if results are not going to be good ? Remember he knows the results ! This is not a blind trial.
Treating dementia of the Alzheimer's type is a terrible challenge that will require an innovative pharmacological strategy simultaneously addressing symptoms and causes of the complex neurodegenerative process involved in Alzheimer's disease. The present review will outline the most recent data, albeit restricted to preliminary preclinical studies, suggesting that the sigma(1) receptor agonist may present some efficacy. The sigma(1) receptor is a unique intraneuronal protein that modulates intracellular Ca(2+) mobilization and extracellular Ca(2+) influx, leading to a wide spectrum of neuromodulatory activity. At the behavioral level, sigma(1)-receptor agonists are antiamnesic and anti-depressant drugs. The sigma(1) receptor is also one of the receptors at which neurosteroids act to exert their rapid nongenomic effects in the brain. In particular, dehydroepiandrosterone (DHEA) is an endogenous sigma(1) agonist and progesterone, a potent antagonist of the sigma(1) receptor. The beta-amyloid protein-related toxicity induces important disturbances of neurosteroid syntheses and releases mechanisms, particularly by affecting the corticotropin-releasing hormone systems. In turn, sigma(1)-receptor agonists showed an enhanced efficacy in animal models of Alzheimer's disease-related learning impairments or depressive responses. In addition, selective sigma(1) agonists, as well as DHEA, showed marked neuroprotective activity in vitro against oxidative stress-related damages. Acting chronically through the sigma(1) receptor may indeed offer a new way to alleviate the cognitive disturbances observed in Alzheimer's disease and promote long-term improvements.
agreed with you , it the current market cap was 800M to 1 billion or higher. At 400m, it is at least a double with strong results for phase 2A. This is because there is NO other AD drug in the running right now, and current drug on market is useless. Market for AD is over 20 billion.
With this, I would think with good 2A, AVXL should be worth 1 billion.
Longs are giving scientific reasons for stock to go up tomorrow, based on the positive data presented. Shorts have NOT ONCE mentioned anything about the data....they just say its going to go down. Why ??
hey pumpers, there is NO new set of data due in December...they are going to present Eplipsy preclinical data, which they already published earlier this year. There is nothing new happening here. Not sure what folks are expecting in December.
I would really question the CEO here...why did he work his news release so that it appears that FDA approved phase 2/3 ?? I think there is bit of pumping by CEO when he saw the stock tank so much.
is about $400M market cap at $3. Remember we still have to do Ph 2B.
$3 is still almost a double from here. If you want AXON type valuation, AVXL needs to show strong 2B too. And remember those warrants.
So I see market cap about 1Billion by late of 2016. A double after 2A. Stock price may not double due to warrants, but still big move.
This talk about $10-$15 in 2015 is not real.
we are doing the reverse..we are moving up because fundamentals are getting much better....